Seeking Alpha

European advisory group backs Astellas Pharma's gilteritinib for certain type of leukemia

|About: Astellas Pharma Inc. (ALPMF)|By:, SA News Editor

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Astellas Pharma Europe B.V.'s (OTCPK:ALPMF) Xospata (gilteritinib) for the treatment of adult patients with FLT3 mutation-positive acute myeloid leukemia (AML).

A positive opinion from the European Commission usually takes ~60 days.

Try Seeking Alpha PREMIUM for unlimited analysis on ALPMF